Drug Profile

Ammuxetine hydrochloride - CSPC Zhongqi Pharmaceutical Technology

Latest Information Update: 20 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Academy of Military Medical Sciences
Class Analgesics; Antidepressants; Anxiolytics; Small molecules
Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Feb 2025 CSPC ZhongQi Pharmaceutical Technology plans a phase III trial for Major Depressive Disorder (PO, Tablet) in February 2025 (NCT06827431)
28 Feb 2023 CSPC ZhongQi Pharmaceutical Technology plans a phase II trial for Major Depressive Disorder(In adults, In the elderly)(PO, Tablet)(NCT05762458)
27 Jul 2022 Phase II trial in Major depressive disorder is ongoing in China (PO, Tablet) (NCT05018013)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com